title: Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment.
authors.forename: Vittorio
authors.initials: V
authors.lastname: Fusco
authors.forename: Anastasios
authors.initials: A
authors.lastname: Loidoris
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Colella
authors.forename: Paolo
authors.initials: P
authors.lastname: Vescovi
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Campisi
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007568:Jaw / Q000473:pathology*; D010020:Osteonecrosis / Q000139:chemically induced*; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid